Hormone replacement therapy (HRT) and anaesthesia

British Journal of Anaesthesia

Volumn 86, Issue 5, 2001, Pages 709-716

  Brighouse, D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Complications, venous thromboembolism; Hormones, hormone replacement therapy

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANESTHESIA; ANESTHESIST; BREAST CANCER; CARDIOVASCULAR DISEASE; COLON CANCER; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LEG FRACTURE; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; SURGERY; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0035040856     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/86.5.709     Document Type: Review

References (60)

1. Carotid artery wall changes in estrogen-treated and -untreated postmenopausal women
2. Plasma lipoprotein levels as predictors of cardiovascular death in women
3. The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women
4. Oral contraceptives and hormone replacement therapy do not increase the incidence or arterial thrombosis in a non-human primate model
5. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus
6. Prevention of venous thromboembolism
7. Prevention of venous thromboembolism
8. Hormone replacement therapy
9. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
10. Antiplatelet therapy for thromboprophylaxis: The need for careful consideration of the evidence from randomised trials
11. Risk of venous thromboembolism in users of hormone replacement therapy
12. Plasma fibrinogen levels in healthy postmenopausal women: Physical activity and hormone replacement status
13. A re-evaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
14. Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes
15. Hormone replacement therapy and risk of colon and rectal cancer
16. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women
17. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
18. Acquired thrombophilia
19. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study
20. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology
21. Hormone replacement therapy and venous thromboembolism
22. Hormone replacement therapy and the risk of thromboembolism: Population based case-control study
23. Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestrodiol patch
24. Effect of hormone replacement therapy on non-invasive cardiovascular haemodynamics
25. Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based case-control study
26. Treatment and prevention of venous thromboembolism
27. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
28. Prevention of venous thromboembolism
29. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
30. Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women
31. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis
32. Prediction of postoperative deep-vein thrombosis
33. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy
34. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women
35. Age-related deterioration in arterial structure and function in postmenopausal women: Impact of hormone replacement therapy
36. Hormone replacement therapy and haemostatic function
37. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators
38. The physician's role in women's decision making about hormone replacement therapy
39. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy
40. Hormone replacement therapy and risk of non-fatal stroke
41. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics
42. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women
43. Prevention of pulmonary embolism and deep venous thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
44. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
45. Osteoporosis: Trials and tribulations
46. Place of aspirin in prophylaxis of venous thromboembolism
47. The effects of hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women
48. Risk of and prophylaxis for venous thromboembolism in hospital patients
49. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors
50. Hormone replacement therapy: Assessment of present use, costs, and trends
51. Cardiovascular disease risk and hormone replacement therapy (HRT): A review based on randomised, controlled studies in postmenopausal women
52. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women
53. Congenital thrombophilia
54. Women with thrombophilia: Assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy
55. The Heart and Estrogen/ Progestin Replacement Study: What have we learned and what questions remain?
56. Venous thrombo-embolism and hormone replacement therapy
57. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
58. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial
59. A meta-analysis of the effect of hormone replacement therapy upon depressed mood